Market Dynamics

Gradual increase in number of patients suffering from eosinophilic asthma across the globe and rapid technological advancements in testing devices are major factors expected to drive the growth of global FeNO testing market. In the United States (U.S.), an estimated 25.7 million people are affected with asthma, and 15% of these people have severe asthma that is difficult to control with standard medications. Eosinophilic asthma is considered a leading cause of severe asthma, affecting 50 to 60 percent of people with the severe form of the disease. FeNO is directly associated with eosinophils in the airways and is elevated in individuals with allergic asthma. Manufacturers are investing high for R&D activities and focused on introduction of innovative solutions i.e. to deliver advanced care to patients. Government of developed and developing countries is changing the diagnostic approach.

Considering the patient care importance they are altering the guidelines related to product use and approvals. In 2017, National Institute for Health and Care Excellence (NICE), recommend the use of FeNO testing as part of comprehensive diagnostic algorithms for adults, children and young people. In particular, NICE recommends FeNO testing for adults when a diagnosis of asthma is being considered, and consideration of a FeNO measurement in children and young people if there is diagnostic uncertainty after initial assessment and normal spirometry, or obstructive spirometry with negative bronchodilator reversibility. Changing guidelines is helping companies in revenue generation which is impacting the growth of target market. NICE recommended the use of FeNO testing as part of asthma diagnosis in 2017. Circassia Pharmaceuticals plc, a manufacturer of Circassia’s NIOX® products made the product available in many countries across Europe, including the UK, as well as the United States, China, Japan and a range of other country.

This helped the company to enhance the business presence overseas.

Strategic business expansion activities by major players in order to increase the revenue share and enhance the product portfolio by innovative product launch is positively impacting in the growth of FeNO testing market. In 2020, Caire Inc, a medical devices manufacturer acquired Spirosure Inc. The acquisition is focused on using Spirosure’s technology to the company’s market-leading oxygen solution portfolio. This acquisition is expected to help the company to enhance the business and increase the revenue share. 

Factors such as high cost of devices and stringent government regulations related to product approval are expected to hamper the growth of global FeNO testing market. In addition, lack of developed infrastructure in developing countries is expected to challenge the adoption of advanced devices which is expected to limit the growth of target market. However, increasing investment by major players for development of low-cost products, increasing government spending on development of infrastructure and focus on integration of advanced analytics for better results are factors expected to create new opportunities for players operating in the FeNO testing market over the forecast period. 

Segment Analysis by Region 

The market in North America is expected to account for major revenue share in the global FeNO testing market due to high patient pool suffering from asthma. Presence of large number of players operating in the country and availability of advanced infrastructure for adoption of advance devices is expected to impact the growth of target market. In addition, increasing business acquisition activities by major players with the focus to increase the revenue share and enhance the product offerings is expected to boost the growth of FeNO testing market.

The market in Asia Pacific is expected to witness faster growth in the target market due to substantial increase in patients suffering from breathing problems. In addition, major players approach towards enhancing the business in emerging economies through strategic merger is expected to boost the growth of regional market.

Competitive Landscape    

The global FeNO testing market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The players profiled in the report are Bedfont Scientific Ltd., Caire, Inc., Medisoft Group, Bosch Healthcare Solutions GmbH, Sunvou, RuiBreath, Circassia, ECO MEDICS AG.

Report coverage 

FeNO Testing Market Segment Analysis, 2019

The global FeNO testing market is segmented into type, indication, distribution channel and end use. The type segment is bifurcated into nitric oxide handheld monitor, nitric oxide standalone monitor and others. Among type the nitric oxide handheld monitor is expected to witness faster growth in the FeNO testing market. The end use segment is divided into hospitals, diagnostic centers, clinics, ambulatory surgical centers, and homecare setting. Among end use the hospital segment is expected to account for major revenue share in the global market.  

Market Segmentation

Market By Type

Nitric Oxide Handheld Monitor
Nitric Oxide Standalone Monitor 
Others

Market By Indications

Eosinophilic Airway Inflammation
Atopic Asthma
Chronic Respiratory Symptoms
COPD with Mixed Inflammatory Phenotype
Eosinophilic Bronchitis
Pulmonary Arterial Hypertension
Corticosteroid Responsiveness
Cystic Fibrosis
Others 

Market By Distribution Channel

Direct Tender
Retail Sales
Online Sales

Market By End Use

Hospitals
Diagnostic Centers
Clinics
Ambulatory Surgical Centers
Homecare Setting

Market By Geography

North America
•    U.S.
•    Canada

Europe
•    U.K.
•    Germany
•    France
•    Spain
•    Rest of Europe

Asia-Pacific
•    China
•    Japan
•    India
•    Australia
•    South Korea
•    Rest of Asia-Pacific

Latin America
•    Brazil 
•    Mexico
•    Rest of Latin America

Middle East & Africa
•    GCC
•    South Africa
•    Rest of Middle East & Africa